Several months after the FDA signed off on Bimzelx’s label expansion into hidradenitis suppurativa (HS), UCB is expanding an existing campaign to include the drug’s new indication. UCB ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and key secondary endpoints. The study assessed 87 children and adults aged 1 ...

United Commercial Bank (UCB), one of the oldest private banks in Bangladesh, looks to return to sustainable profitability within around two years as it takes steps to improve governance, recover ...

UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could pave the way for its use in another epilepsy condition.

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...

Investing.com -- BofA Securities upgraded UCB SA to “buy” from “neutral,” raising its price objective to €225 from €210, citing strong commercial momentum for its inflammatory disease ...

UCB, a global biopharmaceutical company, announced that the phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key ...

UCB presents latest research advancements at European Pediatric Neurology Society Congress 15 scientific abstracts, including three oral presentations demonstrate UCB’s continued commitment to leading ...

Partnering to innovate: UCB pharma Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation.